Ascendis Pharma A/S (NASDAQ:ASND) was the recipient of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 329,544 shares, a decrease of 58.2% from the October 13th total of 787,744 shares. Currently, 1.0% of the shares of the company are sold short. Based on an average daily trading volume, of 165,167 shares, the short-interest ratio is currently 2.0 days.

Shares of Ascendis Pharma A/S (NASDAQ ASND) opened at $36.13 on Monday. Ascendis Pharma A/S has a 12 month low of $18.74 and a 12 month high of $42.00.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Friday, August 18th. The biotechnology company reported ($1.04) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.24). The company had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $0.78 million. Ascendis Pharma A/S had a negative return on equity of 67.76% and a negative net margin of 2,977.70%. Ascendis Pharma A/S’s quarterly revenue was down 61.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.53) EPS. sell-side analysts predict that Ascendis Pharma A/S will post -3.54 EPS for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of ASND. Bank of America Corp DE lifted its holdings in Ascendis Pharma A/S by 23.6% during the 1st quarter. Bank of America Corp DE now owns 5,345 shares of the biotechnology company’s stock worth $150,000 after buying an additional 1,020 shares during the last quarter. Alps Advisors Inc. lifted its holdings in Ascendis Pharma A/S by 7.9% during the 2nd quarter. Alps Advisors Inc. now owns 29,264 shares of the biotechnology company’s stock worth $812,000 after buying an additional 2,144 shares during the last quarter. Bank of Montreal Can lifted its holdings in Ascendis Pharma A/S by 127.4% during the 2nd quarter. Bank of Montreal Can now owns 4,535 shares of the biotechnology company’s stock worth $126,000 after buying an additional 2,541 shares during the last quarter. Victory Capital Management Inc. bought a new position in Ascendis Pharma A/S during the 3rd quarter worth approximately $194,000. Finally, Aperio Group LLC bought a new position in Ascendis Pharma A/S during the 3rd quarter worth approximately $241,000. 65.01% of the stock is owned by hedge funds and other institutional investors.

Several equities analysts recently commented on ASND shares. Bank of America Corporation upped their target price on Ascendis Pharma A/S from $36.00 to $46.00 in a research note on Thursday, September 28th. Wells Fargo & Company reiterated a “buy” rating and issued a $51.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, September 22nd. Credit Suisse Group set a $28.00 target price on Ascendis Pharma A/S and gave the company a “buy” rating in a research note on Tuesday, July 18th. Leerink Swann reiterated a “hold” rating and issued a $28.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, September 1st. Finally, Wedbush reiterated an “outperform” rating and issued a $10.71 target price (down from $65.00) on shares of Ascendis Pharma A/S in a research note on Friday, September 22nd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $36.95.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/ascendis-pharma-as-asnd-short-interest-down-58-2-in-october-3/1699050.html.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with Analyst Ratings Network's FREE daily email newsletter.